ArticleAnnals of biomedical engineering2026
Synchronized Cardiac Support with Veno-Pulmonary Extracorporeal Membrane Oxygenation in a Simulation Mannequin.
Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracorporeal membrane oxygenation (ECMO) traditionally delivers continuous flow, which may be associated with increased pulmonary edema and biotrauma. We hypothesized that electrocardiogram (ECG)-synchronized pulsatile flow may help mitigate these effects.
methodsWe developed a benchtop mannequin simulating a veno-pulmonary (V-P) ECMO configuration, which enables direct return of oxygenated blood to the pulmonary artery and provides a controlled platform to evaluate pulmonary vascular responses. Using this model, we assessed the hemodynamic effects of pulsatile flow delivered by the iCOR (Xenios, Germany). Three clinical severity models were created with varying cardiac output, pulmonary vascular resistance (PVR), and heart rate. Each model was tested under standard ECMO and ECMO with the iCOR. Hemodynamic parameters were measured across various flow rates and iCOR settings.
resultsIn low-resistance models, iCOR effectively increased pulse pressure and reduced diastolic pulmonary artery pressure (PAP) compared to ECMO alone. As PVR increased, the benefits of iCOR were attenuated. Optimal pulse timing and strength were identified for each model, with the greatest effects seen under low to moderate resistance. High resistance and elevated flow rates reduced the effectiveness of pulsatile support.
conclusionECG-synchronized pulsatile flow via iCOR modulated PAP in a resistance-dependent manner. Pulsatile flow enhanced hemodynamics and showed potential to reduce right ventricular afterload under low-resistance conditions. These findings highlight the need for individualized ECMO and iCOR strategies based on pulmonary hemodynamics.
Indexed as
Identifiers
42171879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.